{
    "nct_id": "NCT00357357",
    "title": "Clinical Safety/Tolerability of HF0220 and Its Effect on Biochemical Markers Relevant to Patients With a Diagnosis of Mild to Moderate Alzheimer' Disease",
    "status": "COMPLETED",
    "last_update_time": "2008-08-20",
    "description_brief": "The purpose of this Phase II study is to evaluate the safety and tolerability of HF 0220 in patients with Alzheimer's disease compared to placebo (inactive substance). The study will also validate biochemical markers as appropriate clinical end-points and to assess the suitability of chosen dose levels for future clinical studies.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "HF0220"
    ],
    "placebo": [
        "placebo (inactive substance)"
    ],
    "explanation_target": [
        "Reason: The trial tests HF0220 in patients with mild\u2013moderate Alzheimer\u2019s disease and aims to validate biochemical markers and dose suitability \u2014 language consistent with a disease\u2011modifying/neuroprotective intervention rather than a purely symptomatic cognitive enhancer or a neuropsychiatric symptom treatment. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Act: Public sources (company press releases and trial registries) describe HF0220 as a \"broad\u2011spectrum neuroprotective\" agent and a potential first\u2011in\u2011class disease\u2011modifying candidate for neurodegenerative disease; the Phase II trial was run by Hunter\u2011Fleming / Newron and focused on safety, tolerability and biomarkers. These sources do not identify HF0220 as a biologic (e.g., antibody or vaccine) and consistently present it as a small\u2011molecule neuroprotective compound in development. \ue200cite\ue202turn3search5\ue202turn3search6\ue202turn3search3\ue202turn0search3\ue201",
        "Reflect: Given the trial aims (biomarkers, disease modification) and the drug being described in industry reports as a neuroprotective, clinical\u2011stage compound (with no evidence it is a biologic), the best fit among the provided categories is \"disease\u2011targeted small molecule.\" I note some ambiguity because the exact chemical identity / mechanism of HF0220 is not publicly detailed in the sources I found; if you need definitive molecular classification I can continue searching or look for archived company documents or patents. Key sources used: clinical trial registry entry and industry/press coverage. \ue200cite\ue202turn0search0\ue202turn3search5\ue202turn3search3\ue201"
    ],
    "agent_type": "F) Inflammation",
    "explanation_agent": [
        "Reason: The trial is a Phase II study of HF0220 in mild\u2013moderate Alzheimer\u2019s disease that evaluated safety/tolerability and biomarkers \u2014 language consistent with a disease\u2011modifying/neuroprotective intervention rather than a purely symptomatic treatment. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Act: Public trial records list HF0220 as the investigational drug in NCT00357357 (Phase 2, completed) sponsored by Hunter\u2011Fleming/Newron, and AlzForum classifies HF0220 as a small\u2011molecule therapeutic with the CADRO-relevant target type listed as \u201cInflammation.\u201d Based on those sources, the most specific CADRO match is F) Inflammation. \ue200cite\ue202turn0search0\ue202turn0search1\ue202turn0search4\ue201",
        "Reflect: This classification fits the available public information (trial registry + expert database). There is some ambiguity because detailed molecular mechanism data for HF0220 in public sources is limited (AdisInsight notes trial/results reporting but full mechanistic details are not accessible in that entry), so if an alternative primary mechanism is documented elsewhere (e.g., direct synaptic, metabolic, or proteostasis activity), the CADRO assignment should be revisited. For now, assign F) Inflammation as the best fit. \ue200cite\ue202turn0search3\ue202turn0search4\ue201",
        "Web search results used: (1) Clinical trial registry entry for NCT00357357 showing Phase II safety/tolerability and biomarker aims. \ue200cite\ue202turn0search0\ue201 (2) Aggregated trial listing (MedPath/clinical-trial summary) with status, arms, and completion details. \ue200cite\ue202turn0search1\ue201 (3) AlzForum therapeutic page for HF0220 indicating therapy type = small molecule and target type = Inflammation. \ue200cite\ue202turn0search4\ue201 (4) AdisInsight trial profile noting sponsor and results reporting (summary view; full mechanistic detail behind subscription). \ue200cite\ue202turn0search3\ue201"
    ]
}